ADVERTISEMENT
Dr Spira Talks Amivantamab Plus Lazertinib for Osimertinib-Relapsed, EGFR+ NSCLC
06/09/2021
Alexander Spira, MD PhD, FACP, Virginia Cancer Specialists, discusses the use of amivantamab in combination with lazertinib for the treatment of chemotherapy-naïve patients with osimertinib-relapsed, EGFR+ non-small-cell lung cancer (NSCLC) and potential biomarkers for response, presented at the 2021 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement